41.10 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||35.00 x 1200|
|Ask||43.13 x 1000|
|Day's Range||40.74 - 41.69|
|52 Week Range||35.10 - 45.09|
|Beta (3Y Monthly)||0.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.63|
As Breast Cancer Awareness Month kicks off, Hologic CEO Steve MacMillan speaks to "Squawk Box" about the company's new imaging tech to better help detect cancer.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
In this article I am going to calculate the intrinsic value of Hologic Inc (NASDAQ:HOLX) by projecting its future cash flows and then discounting them to today’s value. I will Read More...
Hologic, Inc. announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2018 on Wednesday, November 7, 2018, after the market closes.
Survey commissioned by Company behind the Genius™ 3D Mammography™ exam sheds light on need for education during Breast Cancer Awareness Month MARLBOROUGH, Mass. , Oct. 1, 2018 /PRNewswire/ -- WHO: ...
Hologic, Inc. (HOLX) announced today that Nancy G. Brinker, global cancer advocate, Hologic consultant and founder of Susan G. Komen, and Krystal Barter, author and founder of Australian nonprofit Pink Hope, will join Steve MacMillan, the Company’s Chairman, President and Chief Executive Officer, and selected employees to ring the Nasdaq Opening Bell for the 13th consecutive year on October 1 to mark the start of Breast Cancer Awareness Month. In addition to appearing at the Nasdaq MarketSite, Hologic will recognize Breast Cancer Awareness Month by announcing the results from their recent survey, conducted online by The Harris Poll among over 1,000 U.S. women, designed to highlight the need for education about breast density and the effect it has on breast cancer screening and cancer detection.
Hologic (HOLX) progresses with initiatives to boost the Breast Health unit. The recent buyout is likely to widen portfolio and fortify Hologic's position in the breast conserving surgery market.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Sept. 26) Abbott Laboratories (NYSE: ABT ) Aldeyra Therapeutics ...
Hologic, Inc. (HOLX), a global leader in women’s health, announced today that it has signed a definitive agreement to acquire Focal Therapeutics, a privately-held company, for $125 million in cash. In conjunction with Hologic’s recent acquisition of Faxitron Bioptics, Focal strengthens the Company’s position in the rapidly growing market for breast conserving surgery. The transaction adds Focal’s innovative BioZorb marker to the Company’s Breast Health product portfolio.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding HOLX is favorable, with net inflows of $27.64 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.
Hologic (HOLX) is a medical technology company focused on women’s health with headquarters in Marlborough, Massachusetts. The company offers solutions across four segments including diagnostics, breast and skeletal health, gynecological surgery, and medical aesthetics. The company recently provided an update on the financial impact of its recently announced marketing and distribution suspension of its TempSure Vitalia handpiece and probes. We discussed the details in the previous article of this series. ...
On September 12, Hologic (HOLX) provided an update on the financial impact of the suspension of its marketing and distribution of the company’s Vitalia handpieces and probes, which it announced in August. The company issued form 8-k on August 13 reporting its decision to suspend the marketing and distribution of the company’s Tempsure Vitalia handpieces and probes. The device, part of the company’s Cynosure division, was recalled on FDA (U.S. Food and Drug Administration) concerns around this class of products, which are used for vaginal rejuvenation procedures. The FDA sent letters to certain companies that manufactured these kinds of devices.
On September 17, Hologic (HOLX) ended the day at $39.53. The stock was down ~0.3% from its previous trading day’s closing price of $39.64. The stock has recuperated some of the losses it saw during the first half of fiscal 2018. It witnessed a declining trend after reporting its 52-week high of $45.09 on January 9, 2018.
NEW YORK, Sept. 13, 2018-- Levi & Korsinsky announces it has commenced an investigation of Hologic, Inc. concerning possible violations of federal securities laws. Hologic is the parent company of Cynosure, ...
An 8-K filed late Wednesday suggests Hologic, Inc. (NASDAQ: HOLX )’s headed for harder times . The Analyst Bank of America Merrill Lynch analyst Derik de Bruin downgraded Hologic from Buy to Neutral and ...
From January 2–28, 2018, Teleflex (TFX) stock rose from $254.73 to $287.65, which was its high point so far in 2018. During the broader market turmoil in February, it dipped to a low of $242.67 on March 1. Then it made a steady recovery to $280 in June but has corrected again to its current level of $248.
Hologic is a medical technology firm focused on developing solutions for women’s health. Year-to-date, Hologic stock is down ~9.6%. The event led to a ~4% decline in its stock price on August 13, when the announcement was made.
On September 6, Hologic (HOLX) ended the day at $38.74. The stock was marginally down from its previous day’s closing price of $39.04. Hologic stock hit a 52-week high of $45.09 at the start of this year, on January 9, 2018.
Teleflex’s (TFX) interest expenses increased from $19.89 million in the second quarter of 2017 to $26.65 million in the second quarter of 2018. Its income taxes, on the other hand, decreased from $12.1 million in the second quarter of 2017 to $9.58 million in the second quarter of 2018.
Teleflex’s (TFX) geographic segments include the United States, Europe, Asia, and other. Teleflex incurred a total cost of sales of $265.09 million in the second quarter of 2018 compared to $238.3 million in the second quarter of 2017. For fiscal 2018, Teleflex’s gross margins are expected to be 57.56% compared to 55.76% for fiscal 2017.
Hologic (HOLX) is a medical technology firm focused on improving women’s health. The company operates across four segments: diagnostics, GYN surgical, breast cancer, and skeletal health. The company reported strong Q3 2018 earnings results, which led to a rise in its stock price. In this article, let’s look at analysts’ recommendations for HOLX stock.
MARLBOROUGH, Mass. , Sept. 6, 2018 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Morgan Stanley 16 th Annual Global Healthcare Conference in New York, ...
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.